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Abstract 
Adoptive therapy with T cell receptor (TCR)-engineered T cells has shown promising results in 
the treatment of patients with tumors, and the number of TCRs amenable for clinical testing is 
expanding rapidly. Notably, adoptive therapy with T cells is challenged by treatment-related side 
effects, which calls for cautious selection of target antigens and TCRs that goes beyond their 
mere ability to induce high T cell reactivity. Here, we propose a sequence of in vitro assays to 
improve selection of TCRs, and exemplify risk assessments of on-target as well as off-target 
toxicities using TCRs directed against Cancer Germline Antigens. The proposed panel of assays 
covers parameters considered key to safety, such as expression of target antigen in healthy 
tissues, determination of a TCR’s recognition motif towards its cognate peptide, and TCR’s 
cross-reactivity towards non-cognate peptides.  
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Introduction 
Therapeutic use of anti-tumor T cells has proven feasible in a multitude of trials over the last 
decade. Alongside the demonstration of clinical benefit and enthusiasm about the therapeutic 
efficacy, the occurrence of toxicities has stimulated awareness of safety pitfalls. While initial 
studies demonstrated recognition, and sometimes destruction of healthy tissues (1-3), later 
studies demonstrated lethal adverse effects in individual patients (4,5). These studies highlight 
the two main challenges facing safety of T cell receptor (TCR) gene therapy: on- and off-target 
toxicities. With a quickly expanding panel of TCRs that have generally been selected for their 
ability to provide T cells with high avidities towards tumor antigens, there is an urgent need for 
streamlining the safety assessment of these TCRs prior to clinical usage. 
 
Selecting target antigens 
An ideal target antigen for adoptive T cell therapy (AT) displays two important features: it is 
immunogenic and shows selective and homogenous expression in tumor tissue. Immunogenicity 
is best explained as an antigen’s ability to be recognized by and sufficiently activate T cells, a 
feature that is generally well addressed when selecting a target antigen and its corresponding 
TCR (reviewed in (6)). In example, characteristics related to the immunogenicity of  two 
MAGE-C2 (MC2) antigen epitopes are summarized in Table I. Selective expression in tumor 
tissue, and hence its absence in healthy tissues, would reduce the risk for on-target toxicities. 
Differentiation, over-expressed or onco-fetal antigens are not absent from healthy tissues and the 
targeting of these antigens, e.g. MART-1 or carcinoembryonic antigen (CEA), by TCR-
transduced T cells has resulted in severe destruction of melanocytes in the eyes, ears and skin (1) 
or inflammation of the colon (2,3). Candidate antigens that are exclusively expressed by tumor 
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tissues include neo-antigens and oncoviral antigens. Neo-antigens are derived from somatic 
DNA alterations and their identification requires analyses of mutations, gene expression, and 
algorithms that predict antigen processing and presentation by major histocompatibility complex 
(MHC) (7-9). AT studies with tumor infiltrating lymphocytes (TILs) in patients with melanoma 
and cholangiocarcinoma showed that clinical benefit was associated with T cell responses 
against neo-antigens (9-11). Current exploitation of neo-antigens in AT, however, is challenged 
by the uncertainty of current algorithms accurately predicting immunogenicity, and the fact that 
neo-antigens are usually specific per patient (12-14). Viral antigens are present in more than 10% 
of human cancers and are often the result of viral insertion into the genome and subsequent 
reactivation in tumors. AT studies using TILs reactive against either HPV or EBV have shown 
clinical successes in patients with cervical cancer or nasopharyngeal carcinoma, respectively 
(15,16). In addition to neo-antigens and onco-viral antigens, also certain cancer germline 
antigens (CGAs) demonstrate tumor-selective expression. In fact, CGAs are expressed in 
gonadal tissues and some in thymus (17), and certain CGAs are considered to be selectively de-
repressed in tumor tissuess (for detailed reviews, see (6,18,19)). MAGE-A3 and NY-ESO1 are 
examples of CGAs that have already been targeted by TCR-engineered T cells in patients with 
metastatic melanoma, metastatic synovial sarcoma or multiple myeloma (4,20). Although off-
target toxicities were observed with the targeting of the former antigen (most likely an issue of 
the TCRs; see next section), the safe use of selected CGAs was suggested by the targeting of 
NY-ESO1 demonstrating clinical benefit without toxicities (20,21). 
We recommend for any antigen, with the exception of neo-antigens, to test the antigen’s absence 
from a large panel of healthy organs. Online databases such as the protein atlas 
(http://www.proteinatlas.org/) or the CGA database (www.cta.lncc.br) combine extensive data 
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from transcriptomic analyses and antibody stainings from numerous normal, non-cancerous cell 
lines and tissues. When applying these tools to assess the expression of MC2, we observed that 
mRNA expression is restricted to cells from cancers and testes, the latter considered to possess 
an immune privileged status (no MHC expression; thus no detection by T cells). The use of 
commercially available cDNA libraries of a large series of healthy tissues enable researchers to 
extend online analyses and quantify antigen expression with a laboratory assay. When 
performing qPCR using such a cDNA library, we demonstrated absence of MC2 mRNA in 
healthy tissues as illustrated in figure 1A. In case specific antibodies are available, we would 
recommend to follow-up qPCR with immune histochemistry. Using an MC2-specific antibody, 
we confirmed the presence of MC2 protein in testis and melanoma as well as its absence in 
multiple healthy tissues, such as brain, heart, intestine and lung (see figure 1B). However, both 
qPCR and immune histochemistry cannot formally exclude the presence of rare antigen-positive 
cells within a tissue, e.g. stem cells. For example, mRNA of certain CGAs has been detected 
only in medullary thymic epithelial cells but not total thymus (17). As an additional means to 
exclude target antigen expression, sophisticated in vitro cell cultures have been developed to 
closely mimic complete tissues or organs (commented in next section) (5,22). 
 
Selecting therapeutic TCRs 
Once the safety of the target antigen has been assessed, one can start selecting TCRs. Procedures 
to obtain tumor-reactive T cells and hence TCRs can generally be divided into those that rely on 
tolerant and those that rely on non-tolerant repertoires of T cells. Tolerant repertoires, where 
deletion of T cells with an avidity outside the thymic selection window has occurred, have been 
used to obtain T cell clones from patients following successful TIL therapy, peptide vaccination, 
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or using in vitro pulsing of autologous dendritic cells (23,24). Notably, the thymic selection of T 
cells is most likely a trade-off between producing a self-tolerant yet sufficiently diverse and 
responsive TCR repertoire, and escape of self-reactive TCRs cannot be negated. Indeed, TCRs 
specific for over-expressed antigens and obtained from the native repertoire have been shown to 
initiate autoimmune side effects (1). The use of non-tolerant repertoires, with the rationale of 
allowing the generation of high-avidity T cells, has been applied in allogeneic in vitro as well as 
in vivo systems. For example, HLA-mismatched antigen-presenting cells (25) or artificial 
antigen-presenting cells pulsed with peptides of interest facilitate the in vitro generation of 
tumor-reactive T cells (26). In vivo, mice transgenic for human HLA as well as mice transgenic 
for human TCR and HLA-A2 genes (27) have been immunized and used as a source of TCRs. 
After having obtained antigen-reactive T cells, sequences of the TCRα and β chains can be 
determined by molecular techniques such as 5′ RACE (23), enhanced PCR methods, capturing 
and indexing of genomic DNA-encoding TCR chains (28), or sequencing and pairing of TCR 
chains based on combinatorial algorithms (29). 
It is important to note that TCRs derived from above-mentioned repertoires, in particular the 
non-tolerant repertoir, have not been selected in the presence of all patient MHC alleles and in 
the case of mice neither against human peptides present in the thymus, and may show allo- and 
non-cognate reactivity. Moreover, TCRs, even though obtained from highly tumor-reactive T 
cells, have an inherent degeneracy for peptide recognition and are able to recognize more than a 
single peptide. This dynamic flexibility in antigen recognition is in part accredited to the bending 
ability of the TCR-CDR domains (30,31), but also to the dominant interaction of the TCR with a 
restricted number and order of amino acids present in the MHC-presented peptide. To minimize 
the risk of selecting a TCR that recognizes non-cognate self-peptides, we recommend a series of 
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assays that assess the risk of this so-called off-target toxicity. These assays are illustrated with 
two patient-derived MC2-specific TCRs 6 and 16 with details and evaluation of anti-tumor T cell 
responses mediated by TCR6 and TCR16 summarized in Table I. 
 
Recognition of random epitopes 
Initial assessment of a TCR’s self-reactivity can be done by testing the responsiveness of TCR-
transduced T cells towards random peptides known to be presented by the respective HLA 
restriction allele. Mathematical projections indicate that amongst a pool of ~10
12
 peptides, a 
single TCR may react with >10
6
 peptides, supporting the notion of TCR degeneracy for peptide 
recognition, which potentially contributes to a more diverse TCR repertoire (32). We co-cultured 
TCR6 and TCR16 T cells with antigen-presenting cells loaded with saturating concentrations of 
>100 common, HLA-A2-eluted self-peptides (4). As depicted in figure 2, both T cell populations 
mediated a T cell response to their respective cognate peptides, but to none of the other peptides. 
Importantly, these data hint to lack of cross-reactivity of these two TCRs, but we cannot fully 
exclude recognition to random peptides. Another assessment of self-reactivity can be conducted 
by testing TCR-transduced T cells towards allogenic HLA molecules. In order to exclude 
activation of T cells upon recognition of foreign HLA molecules, panels of lymphoblastoid B 
cell lines with various HLA allotypes have proven valuable (33,34).  
 
Recognition of cognate epitope via critical amino acids 
Further assessment of a TCR’s self-reactivity, and a key assay in this communication, is the 
testing of a TCR’s intrinsic capacity to recognize peptides highly homologous to its cognate 
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epitope (35,36). To this end, one can determine the recognition motif, i.e. the position and 
sequence of amino acids within the cognate epitope that are crucial for binding to the TCR. This 
motif is unique per TCR and can be considered a surrogate measure for the extent of cross-
reactivity of TCRs (22,33). The importance to assess such motifs became apparent from two 
recent clinical trials using AT with TCR-engineered T cells. The first trial targeting MAGE-A3 
and A9 (MA3/9) in the context of HLA-A2 utilized the TCR 9W11 and reported neurological 
toxicities in two patients with metastatic melanoma (4). The second trial targeting MA3 in the 
context of HLA-A1 utilized the TCR a3a and reported cardiac toxicities in one patient with 
metastatic melanoma and one patient with multiple myeloma (5). Both TCRs were affinity 
enhanced in vitro and mediated toxicity by recognizing peptides highly similar to the cognate 
peptide, namely peptides derived from MAGE-A12 and Titin present in brain and heart tissue, 
respectively. These studies clearly underline the need to assess recognition motifs, and the search 
for T cell reactivities against homologous self-peptides, prior to clinical application. The 
importance of recognition motifs is timely and its assessment has only occurred for a limited 
number of TCRs to date, which is summarized in Table II.   
Using a set of altered peptide ligands (APLs), peptides containing individual alanines 
replacements at every single position in the cognate peptide (in case of an endogenous 
alanine→glycine), we conducted stimulation assays with TCR6 and 16 T cells. Critical amino 
acids are defined as those that, when testing the respective APLs, result in a drop of the T cell 
response (generally using IFN production as a readout) of > 50% when compared to the 
response toward the cognate peptide. Following the determination of these motifs, as exemplified 
in figure 3A, we used ScanProSite (http://prosite.expasy.org/scanprosite/) (37) and identified 
target antigens, listed in figure 3B, that harbor the recognition motif and represent potential 
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cross-reactive targets for TCRs 6 and 16. Subsequently, these self-peptides were tested for their 
ability to induce T cell responses towards HLA-A2-postive antigen presenting cells loaded with 
saturating concentrations (1µM) of peptide. These experiments yielded a short list of self-
peptides that are actually recognized by the TCRs under study, defined as those that resulted in at 
least a T cell IFNγ response > 2.5% of the response to cognate peptide (figure 3B: underlined 
antigens).  
 
Recognition of non-cognate epitopes that contain recognition motif 
Once self-peptides that can be recognized by TCR T cells have been identified, we recommend 
to execute two additional tests to more stringently assess the risk for self-reactivity. These tests 
aim to provide measures for T cell avidity as well as efficiency of cellular processing and 
presentation. Towards the first test, one can titrate amounts of non-cognate peptides and 
determine the concentration of these peptides that elicits 50% of the maximal T cell response 
(EC50). For both TCR6 and 16 T cells, we found that only a single self-peptide, namely a peptide 
from the antigen MAGE-B4 (MB4) or MAGE-C1 (MC1; see figure 3B for homology and 
predicted peptide-HLA binding), respectively, revealed detectable EC50 values that were only 2-
5 fold lower than those of the cognate peptides (figure 4). Extent of homology and predicted 
peptide-MHC binding of peptides that induce T cell IFN are listed in figure 3B, which shows 
that loss of homology and peptide-MHC affinity was least affected for MB4 and MC1 peptides. 
All other self-peptides revealed no T cell reactivities at titrated doses, or at the very best 5 log 
scales lower compared to cognate peptide. These were considered not recognizable by the TCRs 
under study and excluded from further assays. Towards the second test, one can predict whether 
self-peptides are the result of antigen processing and presentation to enable T cell recognition in 
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vitro. NetCTLpan (http://www.cbs.dtu.dk/services/NetCTLpan/) (38) takes proteasomal C 
terminal cleavage, TAP transport efficiency, and peptide MHC class I binding of peptides into 
account, and can be employed to obtain an initial score for antigen processing and presentation. 
Analysis of the MB4 peptide, but not MC1 peptide, yielded a high score according to this web-
based tool. Such predictions may not be fully accurate and should be verified using cells known 
to express the antigen or antigen presenting cells (e.g. dentritic cells) transfected with antigen-
encoded RNA followed by co-cultivation with TCR-transduced T cells. To this end, we 
stimulated TCR T cells with the esophageal cancer cells line OEC-19, which natively expresses 
the MB4 and MC1 antigens, but is devoid of the MC2 antigen, and observed that both TCRs 
failed to initiate T cell activation against either MB4 or MC1 (see figure 4B). When using cell 
lines that natively express the MC2 antigen, as a control for the processing and presentation of 
MAGE antigens, we observed that both TCRs did initiate T cell activation. It is noteworthy that 
standard tissue culture systems may not always accurately reflect antigen processing and 
presentation. This was evidenced by the recognition of Titin by the TCR a3a that could only be 
observed in more elaborate tissue culture systems, such as 3D cultures of beating cardiomyocytes 
derived from induced pluripotent stem cells (22). In case the above two assays do not exclude 
self-reactivity of TCR T cells, one could pursuit assessment of the tumor-selective expression of 
such new antigens. In case expression of new antigens is not selective for tumors, the 
corresponding TCR should be excluded. Using online tools (39) as well as qPCR (figure 1A), 
MB4 showed expression within epididymis and vagina, whereas MC1 showed no expression in 
any of the healthy non-gonadal tissues. These data highlight the stringent safety profile of 
TCR16, the TCR selected for a clinical trial to treat melanoma and head-nand-neck carcinoma, 
currently prepared at Erasmus MC. 
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Future perspective of in vitro assays assessing risk of TCR-mediated toxicities 
The proposed collection and sequence of in vitro assays to assess risks for toxicities are 
presented in figure 5. We advocate this testing for TCRs with clinical intent, in particular those 
TCRs reactive against a self-peptide and derived from a non-tolerant repertoire and/or following 
gene-enhancement. In extension to gene-enhancement, introduction of TCR-CDR mutations has 
been a commonly used tool to generate high-affinity TCRs (2,4,5,20). While such gene-enhanced 
TCRs recognize target peptides at increased affinities when compared to the corresponding wild-
type TCRs, consequently such TCRs are also at risk to recognize non-cognate peptides. To test 
whether affinity enhancement led to an increase in degeneracy for peptide recognition, we made 
use of a panel of 8 TCRs specific for the same cognate peptide gp100181-188:HLA-A2) but 
harboring 2-3 mutated amino acids in either their CDR2β, CDR3α or CDR3β domains (Govers, 
Ms submitted). Upon assessment of the recognition motifs and search for motif-harboring self-
peptides, it became apparent that enhanced affinity was accompanied by drastic increase in the 
TCR’s ability to recognize self-peptides (Table III). These data extend earlier findings regarding 
a correlation between affinity enhancement and loss of TCR specificity (40), and warrant caution 
when trying to change the TCR-CDR structure as it compromises the stringet recognition of 
cognate peptide (31,41).   
Taken together, here we propose a platform of in vitro assays that in combination with available 
online-databases and tools allows for optimal toxicity risk-assessment for target antigens and 
TCRs currently under consideration for clinical trials.  
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Figure Legends 
Figure 1. Target antigen is absent or shows restricted expression in healthy tissues. 
(A) MC2, MC1 and MB4 qPCRs were performed on a cDNA library of 48 healthy, human tissue 
samples (OriGene Technologies). Patient-derived melanoma cell line EB81-MEL and patient-
derived esophageal cancer cell line OEC-19 served as positive controls. Spiking experiments 
were conducted separately to determine optimal PCR conditions for maximum sensitivity 
(detection limit: 1:1,000-10,000 MC2
+ 
cell: MC2
- 
cells; data not shown). Relative mRNA levels 
are corrected for GAPDH and expressed as fold increase compared to antigen expression in the 
testis. Part of the displayed data is derived from (23); Copyright © 2016 The American 
Association of Immunologists, Inc. (B) Immune stainings of melanoma and healthy tissues were 
conducted using a monoclonal antibody specific for MC2 (42) on tissue micro arrays (TMA). 
EnVision System (Agilent Technologies) was used for signal visualization, TMAs were scanned 
via Nano zoomer (Hamatsu) and manually scored using Distiller (SlidePath). Exemplary tissue 
sections of patient-derived melanoma tissue as well as various healthy tissues obtained from the 
Erasmus MC pathology department are displayed with 20x magnification. MC2 positivity is 
scored as brown colored nuclear staining, with 3 smaller TMAs exemplifying different staining 
intensities. 
 
Figure 2. TCRs do not recognize random peptides eluted from the restricting MHC allele. 
TCR6 or TCR16 T cells were co-cultured with T2 cells loaded with 1µM of 114 different HLA-
A2-eluted peptides (4) for 24h. Cognate MC2 peptides (TCR6: LLFGLALIEV; TCR16: 
ALKDVEERV) served as positive controls. IFNγ levels in 24h culture supernatants were 
measured by ELISA and are displayed as mean ± SEM (n=3). Left-hand panel is adapted from 
(23); Copyright © 2016 The American Association of Immunologists, Inc. 
 
Figure 3. TCRs recognize cognate peptide via unique or restricted motif. 
(A) TCR6 or TCR16 T cells were co-cultured with T2 cells loaded with 1µM of cognate peptides 
or peptides with a single alanine replacement (Altered Peptide Ligands (APL), in case of alanine 
in original peptide: glycine). IFNγ levels in 24h culture supernatants were measured by ELISA. 
IFNγ response to APLs is displayed as mean % relative to response to cognate peptides ± SEM 
(n=4). Responses < 50% (dashed line) were indicative of amino acids critical for TCR 
recognition (recognition motif: underlined amino acids). (B) Homologous motifs from (A) were 
queried against a human protein database using ScanProSite. This yielded 27 and 1 non-cognate 
matches for TCR6 and TCR16, respectively. Subsequently, TCR6 or TCR16 T cells were co-
cultured with T2 cells loaded with 1µM of these 27 and 1 peptide(s), and IFNγ levels were 
measured in 24h culture supernatants by ELISA (n=4). Underlined peptides induced a T cell 
16 
 
IFNγ response > 2.5% of the response to cognate peptide. Homology to cognate peptide 
(diverging amino acids underlined) as well as peptide-MHC affinity (IC50 calculations according 
to NetMHCpan; http://www.cbs.dtu.dk/services/NetMHCpan/) are indicated for those peptides 
with a detectable IFNγ response. 
 
Figure 4. TCRs mediate negligible T cell avidity nor recognize natively presented non-
cognate peptides that harbor recognition motif. 
(A) Non-cognate peptides underlined in figure 3B were titrated from 10µM (10
-5
M) to 1pM (10
-
12 M) and tested for T cell IFNγ response as described in previous legends and displayed as mean 
± SEM (n=4). EC50 values for cognate and selected non-cognate peptides were calculated in 
GraphPad, using non-linear regression; n.d. = not detectable. (B) TCR6 or TCR16 T cells were 
co-cultured with tumor cell lines or T2 cells (as a negative control). Expression status of MC2, 
MC1, MB4 and HLA-A2 for these cells was assessed via qPCR and indicated below plots with 
plus or minus. IFNγ levels in 24h culture supernatants were measured by ELISA and are 
displayed as mean ± SEM (n=3). Left-hand plots are adapted from (23); Copyright © 2016 The 
American Association of Immunologists, Inc. 
 
Figure 5. Platform of in vitro assays to select antigens and TCRs with limited risk for in 
vivo toxicity. 
Flowchart proposes a series and sequence of in vitro techniques, exemplified in figures 1 to 4 
and explained in detail in text. Such a sequence of assays would facilitate selections of 
potentially safe target antigens and TCRs prior to their use in clinical trials. 
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Table I  Properties of cognate MAGE-C2 epitopes and corresponding TCRs that relate to T cell   
reactivity 
Epitopes 
 LLFGLALIEV 
(MAGE-C2191-200) 
 
ALKDVEERV 
(MAGE-C2336-344) 
HLA-A2 binding 
 predicted affinitya:               9.9nM 
measured affinityb:              2.5µM 
 
predicted affinitya:           342.2nM 
measured affinityb:          20.0µM 
     
TCR 
 
TCR 6  TCR 16 
TCR genesc 
 α-chain:  Vα12-2*01 / Jα23*01 / Cα 
β- chain: Vβ15*02 / Jβ2-3*01 / Cβ2 
 
α-chain:  Vα3*01 / Jα3*01 / Cα 
β- chain: Vβ28*01 / Jβ2-5*01 / Cβ2 
pMHC bindingd 
 EC50 CD8
+ T cells: 348nM 
EC50 CD4
+ T cells: 501nM 
 
EC50 CD8
+ T cells: 663nM 
EC50 CD4
+ T cells:      n.d.   
functional T 
cell aviditye 
 
EC50: 3.19nM  EC50: 73.8nM 
tumor cell 
recognitionf 
 
EB81-MEL: 
518-A2: 
607-B: 
SCC-9: 
93-VU-120: 
SUM-195-PT: 
1090pg/ml 
605pg/ml 
835pg/ml 
311pg/ml 
292pg/ml 
217pg/ml 
 
EB81-MEL: 
518-A2: 
607-B: 
SCC-9: 
93-VU-120: 
SUM-195-PT: 
 
1738pg/ml 
461pg/ml 
626pg/ml 
207pg/ml 
26pg/ml 
466pg/ml 
 
a according to http://www.cbs.dtu.dk/services/NetCTLpan/. 
b T2 cells were pulsed with titrated amounts of ALK or LLF peptide and formation of pMHC class I complexes on the 
cell surface was quantified via flow cytometry using PE-labeled HLA-A2 mAb (23). 
c cDNAs derived from patient-derived T cell clones were PCR amplified using either a set of TCR-Vα or Vβ sense 
primers and a corresponding TCR-Cα or Cβ antisense primer or 5’RACE (rapid amplification of cDNA ends). 
Following nested PCRs and cloning, TCRα and β sequences were identified using www.imgt.org and classified 
according to the Lefranc nomenclature (see (23) for details). 
d TCR T cells were pulsed with titrated amounts of PE-labeled pMHC multimer, and binding was quantified via flow 
cytometry. 
e TCR T cells were antigen-presenting cells that were pulsed with titrated amounts of cognate peptide, and 
functional T cell avidity was quantified via ELISA measurements of IFNγ production. 
f TCR-transduced T cells were co-cultured with 3 melanoma, 2 head-and-neck carcinoma and 1 triple-negative 
breast cancer cell lines all positive for HLA-A2 and MC2 (determined by qPCR) at an E:T ratio of 3:1 for 24h. Cell 
lines were treated with epigenetic drugs Azacytidine and Valproate as well as IFNγ prior to co-culture (see (23) for 
details). IFNγ levels in 24h culture supernatants were measured by ELISA; displayed values are means of five 
experiments. Note that epigenetic drugs induce enhanced and tumor-selective expression of MC2 in vitro (23) as 
well as enhanced tumor immunogenicity in vivo (18). 
n.d. = not determined. 
18 
 
Table II           Recognition motifs of TCRs utilized in clinical and pre-clinical research 
TCR name 
target 
antigen 
HLA 
restriction 
cognate 
epitope 
recognition 
motifa 
number of 
antigens 
with motifb 
number of 
epitopes with 
high MHC affinity 
(<10µM)c 
reference 
a3a MAGE-A3 A1 EVDPIGHLY ExDPIxxxY 5 0 (22) 
9W11 MAGE-A3 A2 KVAELVHFL -xxE-xH--d - - (43) 
T1367 MAGE-A1 A2 KVLEYVIKV xxxEYxIKx 62 6 (33) 
s24-TCR survivin A2 ELTLGEFLKL xLTxGEFLKx 1 1 (44) 
gp100 wt gp100 A2 YLEPGPVTA xLEPGPxxA 4 4 
Govers, Ms. 
submitted 
fl-MPD  gp100 A2 YLEPGPVTA YxEPxxxxx >1000 >500 (45) 
fl-296  gp100 A2 YLEPGPVTA YxExxxxxx >1000 >500 (45) 
TCR 4 MAGE-C2 A2 LLFGLALIEV xxFGLxLxxx 260 122 (23) 
TCR 6 MAGE-C2 A2 LLFGLALIEV LxFxLxLxEx 28 9 (23) 
TCR 11 MAGE-C2 A2 LLFGLALIEV xxFGLxLxEx 21 17 (23) 
TCR 16 MAGE-C2 A2 ALKDVEERV xLKDVEERx 2 2 (23) 
aRecogniton motifs are defined through T cell IFNγ production in response to alanine scanned cognate epitopes.  
bnumber of human proteins containing matching recognition motif according to ScanProSite 
(http://prosite.expasy.org/scanprosite/). 
cnumber of proteins containing matching recognition motif (according to b) and a predicted affinity value <10M 
for binding of the peptide to its respective MHC; affinity calculations according to NetMHCpan 
(http://www.cbs.dtu.dk/services/NetMHCpan/). 
drecognition motif incomplete, amino acids on positions 2-4 and 6-7 are based on stimulation assays conducted by 
Chinnasamy et al. with a panel of MAGE-peptides with highly similar sequences (43); ‘-‘ indicates amino acids with 
unknown relevance to the recognition motif. 
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Table III          TCR affinity enhancement and its effect on off-target recognitiona 
TCR name 
KD 
[μM] 
target antigen 
cognate 
epitope 
recognition 
motifa 
number of 
antigens 
with motifb 
number of 
epitopes with 
high MHC affinity 
(<10µM)c 
gp100 wt 18.5 gp100/HLA-A2 YLEPGPVTA xLEPGPxxA 4 4 
gp100 TCR 1 7.9 gp100/HLA-A2 YLEPGPVTA xLExGPxxA 23 13 
gp100 TCR 2 4.0 gp100/HLA-A2 YLEPGPVTA xLExGPxxx 240 97 
gp100 TCR 5 1.1 gp100/HLA-A2 YLEPGPVTA xLExGPxxx 240 97 
gp100 TCR 8 0.026 gp100/HLA-A2 YLEPGPVTA xLxxxxxxx >10000 >10000 
 
aGovers, Ms, submitted. 
bnumber of human proteins containing matching recognition motif according to ScanProSite 
(http://prosite.expasy.org/scanprosite/). 
cnumber of human proteins containing matching recognition motif (according to b) and a predicted affinity value of 
<10M for binding of the peptide to its respective MHC; affinity calculations according to NetMHCpan 
(http://www.cbs.dtu.dk/services/NetMHCpan/). 
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Figure 3:
1 MAGE-C2 (cognate)*
2 MAGE-B4
3 MAGE-B10
4 ATP-binding cassette subfamily C member 11
5 BTB/POZ domain-containing protein 3
6 CDK5 and ABL1 enzyme substrate 1
7 Coiled-coil domain-containing protein 148
8 Cilia- and flagella-associated protein 43
9 Dynein assembly factor 3, axonemal
10 Probable ATP-dependent RNA helicase DDX 58
11 ELM2 and SANT domain-containing protein 1
12 Probable E3 ubiquitin-protein ligase HERC4
13 Heparan sulfate glucosamine 3-0-sulfotransferase
14 Kinetochore-associated protein 1
15 Melanoma-associated antigen B1
16 Mirror-image polydactyly gene 1 protein
17 Myosin-15
18 Proteasome subunit beta type-3
19 26S proteasome non-ATPase regulatory subunit 6
20 SRR1-like protein
21 Titin
22 Zinc finger protein 578
23 Zinc finger protein 766
24 Zinc finger protein 880
25 Zona pellucida spem-binding protein 3
26 Major facilitator superf, domain-contain. Prot. 1
27 RcPSMB3
28 C3orf67 protein
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